ABVC BioPharma, Inc.

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company focused on developing drugs and medical devices to address unmet medical needs. The company's product pipeline includes ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for pancreatic cancer; ABV-1702 for myelodysplastic syndromes; ABV-1601 for depression in cancer patients; and ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage. ABVC BioPharma, Inc. generates revenue through the development and commercialization of these innovative therapies.

Products

• ABV-1501

• ABV-1504

• ABV-1505

• ABV-1703

• ABV-1702

• ABV-1601

• ABV-1701 Vitargus